Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance
Authors
Keywords
-
Journal
Cancers
Volume 9, Issue 12, Pages 67
Publisher
MDPI AG
Online
2017-06-12
DOI
10.3390/cancers9060067
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer
- (2017) John D. Norris et al. JOURNAL OF CLINICAL INVESTIGATION
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer
- (2017) Ping Mu et al. SCIENCE
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
- (2017) Sheng Yu Ku et al. SCIENCE
- N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
- (2016) Etienne Dardenne et al. CANCER CELL
- Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer
- (2016) Brett S. Carver CANCER CELL
- N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
- (2016) John K. Lee et al. CANCER CELL
- Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
- (2016) Isabel Coutinho et al. ENDOCRINE-RELATED CANCER
- Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain
- (2016) Carmen A. Banuelos et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
- (2016) Julie N. Graff et al. Oncotarget
- Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer
- (2016) Chengfei Liu et al. Oncotarget
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2016) Alexander W. Wyatt et al. JAMA Oncology
- Serial blood-based analysis of AR-V7 in men with advanced prostate cancer
- (2015) M. Nakazawa et al. ANNALS OF ONCOLOGY
- Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
- (2015) S Salvi et al. BRITISH JOURNAL OF CANCER
- Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer
- (2015) C. Liu et al. CANCER RESEARCH
- Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer
- (2015) Consuelo Buttigliero et al. CANCER TREATMENT REVIEWS
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
- (2015) Y. Yamamoto et al. CLINICAL CANCER RESEARCH
- The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
- (2015) H. Gevensleben et al. CLINICAL CANCER RESEARCH
- Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
- (2015) A. M. Aparicio et al. CLINICAL CANCER RESEARCH
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance
- (2015) DJ Crona et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
- (2015) Jan Kroon et al. ENDOCRINE-RELATED CANCER
- Direct effects of the selective CYP17 lyase (L) inhibitor, VT-464, on the androgen receptor (AR) and its oral activity in an F876L tumor mouse xenograft model.
- (2015) William R. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
- (2015) Zhenfei Li et al. NATURE
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
- (2015) Siu Chiu Chan et al. NUCLEIC ACIDS RESEARCH
- Plasma AR and abiraterone-resistant prostate cancer
- (2015) Alessandro Romanel et al. Science Translational Medicine
- Androgen receptor aberrations in the era of abiraterone and enzalutamide
- (2015) Florian Jentzmik et al. WORLD JOURNAL OF UROLOGY
- Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo
- (2015) Andrew K. Kwegyir-Afful et al. Oncotarget
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer
- (2015) Juan Miguel Mosquera et al. NEOPLASIA
- Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2014) C. Liu et al. CLINICAL CANCER RESEARCH
- Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
- (2014) E. J. Chen et al. CLINICAL CANCER RESEARCH
- Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer
- (2014) Kathryn E Ware et al. ENDOCRINE-RELATED CANCER
- Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer
- (2014) David D Chism et al. Expert Review of Anticancer Therapy
- The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors
- (2014) Ning Xie et al. INTERNATIONAL JOURNAL OF CANCER
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
- (2014) P. J. Toren et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor clone dynamics in lethal prostate cancer
- (2014) S. Carreira et al. Science Translational Medicine
- Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer
- (2014) Masis Isikbay et al. Hormones & Cancer
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer
- (2013) N. Mitsiades CANCER RESEARCH
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
- (2013) Kai-Hsiung Chang et al. CELL
- Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
- (2013) H.-L. Tan et al. CLINICAL CANCER RESEARCH
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
- (2013) Andres Jan Schrader et al. EUROPEAN UROLOGY
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
- (2013) T Karantanos et al. ONCOGENE
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors
- (2012) N. Mitsiades et al. CANCER RESEARCH
- Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
- (2012) R. Hu et al. CANCER RESEARCH
- Progress in emerging therapies for advanced prostate cancer
- (2012) Stéphane Oudard CANCER TREATMENT REVIEWS
- Stepwise androgen receptor dimerization
- (2012) M. E. van Royen et al. JOURNAL OF CELL SCIENCE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- (2011) C. Cai et al. CANCER RESEARCH
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
- (2011) Elahe A. Mostaghel et al. CLINICAL CANCER RESEARCH
- Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate Cancer
- (2011) Peter S. Nelson JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
- (2011) Emma Hörnberg et al. PLoS One
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
- (2011) H. Beltran et al. Cancer Discovery
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
- (2010) Karen E. Knudsen et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven
- (2009) G. Attard et al. CANCER RESEARCH
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search